DK1713912T3 - Modificerede Korte Interfererende RNA (Modificerede siRNA) - Google Patents
Modificerede Korte Interfererende RNA (Modificerede siRNA)Info
- Publication number
- DK1713912T3 DK1713912T3 DK05700612.4T DK05700612T DK1713912T3 DK 1713912 T3 DK1713912 T3 DK 1713912T3 DK 05700612 T DK05700612 T DK 05700612T DK 1713912 T3 DK1713912 T3 DK 1713912T3
- Authority
- DK
- Denmark
- Prior art keywords
- modified
- interfering rna
- short interfering
- sirna
- modified sirna
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title 2
- 239000004055 small Interfering RNA Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400145 | 2004-01-30 | ||
| PCT/DK2004/000192 WO2004083430A2 (en) | 2003-03-21 | 2004-03-22 | SHORT INTERFERING RNA (siRNA) ANALOGUES |
| DKPA200401079 | 2004-07-08 | ||
| PCT/DK2005/000062 WO2005073378A1 (en) | 2004-01-30 | 2005-01-28 | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1713912T3 true DK1713912T3 (da) | 2013-12-16 |
Family
ID=36997281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05700612.4T DK1713912T3 (da) | 2004-01-30 | 2005-01-28 | Modificerede Korte Interfererende RNA (Modificerede siRNA) |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080249039A1 (da) |
| EP (1) | EP1713912B1 (da) |
| DK (1) | DK1713912T3 (da) |
| WO (1) | WO2005073378A1 (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1606406T4 (da) | 2003-03-21 | 2013-12-16 | Santaris Pharma As | Short Interfering RNA (siRNA) Analogues |
| EP1893758B1 (en) * | 2005-06-20 | 2014-12-24 | Oligomer Sciences AB | Hybridization-stabilizing construct |
| US20090018097A1 (en) * | 2005-09-02 | 2009-01-15 | Mdrna, Inc | Modification of double-stranded ribonucleic acid molecules |
| WO2007085485A2 (en) * | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
| WO2007107162A2 (en) | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| JP5723154B2 (ja) * | 2007-09-19 | 2015-05-27 | アプライド バイオシステムズ リミテッド ライアビリティー カンパニー | ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型 |
| JP2011528910A (ja) * | 2008-07-25 | 2011-12-01 | アルニラム ファーマスーティカルズ インコーポレイテッド | センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進 |
| WO2011008982A1 (en) * | 2009-07-15 | 2011-01-20 | Sah Dinah W Y | Treatment of neurological disorders |
| EP2456870A1 (en) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| EP2544703A4 (en) | 2010-03-12 | 2013-09-18 | Brigham & Womens Hospital | METHODS OF TREATING VASCULAR INFLAMMATORY DISORDERS |
| ES2699630T3 (es) | 2010-04-23 | 2019-02-12 | Cold Spring Harbor Laboratory | Novedosos ARNhc diseñados estructuralmente |
| EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| WO2012097261A2 (en) | 2011-01-14 | 2012-07-19 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
| CN104011210B (zh) | 2011-10-11 | 2018-05-01 | 布里格姆及妇女医院股份有限公司 | 神经退行性病症中的microRNA |
| EA201492120A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии atp2a2 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| BR112014028631A2 (pt) | 2012-05-16 | 2017-10-17 | Rana Therapeutics Inc | composições e métodos para modulação da expressão da família de genes da hemoglobina |
| WO2013173638A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating smn gene family expression |
| KR20160074368A (ko) | 2012-05-16 | 2016-06-28 | 라나 테라퓨틱스, 인크. | Utrn 발현을 조절하기 위한 조성물 및 방법 |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| MX391977B (es) | 2013-06-27 | 2025-03-21 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9). |
| EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| AU2015308721B2 (en) | 2014-08-29 | 2021-04-01 | Children's Medical Center Corporation | Methods and compositions for the treatment of cancer |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| US10174322B2 (en) * | 2015-02-24 | 2019-01-08 | National Cheng Kung University | Short interfering RNA for treating cancer |
| WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
| US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
| JP2018524588A (ja) | 2015-06-26 | 2018-08-30 | ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド | 骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法 |
| WO2017066796A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
| WO2017066712A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
| US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
| DK3419665T3 (da) | 2016-02-25 | 2025-01-13 | Brigham & Womens Hospital Inc | Behandlingsfremgangsmåder til fibrose ved målretning af SMOC2 |
| US11459568B2 (en) | 2016-10-31 | 2022-10-04 | University Of Massachusetts | Targeting microRNA-101-3p in cancer therapy |
| WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
| EP3668968A1 (en) | 2017-08-14 | 2020-06-24 | Sanford Burnham Prebys Medical Discovery Institute | Cardiogenic mesoderm formation regulators |
| ES3040707T3 (en) | 2017-11-01 | 2025-11-04 | Dana Farber Cancer Inst Inc | Usp1 or uaf1 inhibitors for use in treating cancer |
| WO2020047229A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| AU2019344006B2 (en) | 2018-09-21 | 2025-11-27 | University Of Connecticut | Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome |
| WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
| US20240240183A1 (en) * | 2021-05-25 | 2024-07-18 | National University Corporation Tokyo Medical And Dental University | Heteronucleic acid containing scpBNA or AmNA |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL149694A0 (en) * | 1999-12-23 | 2002-11-10 | Exiqon As | Therapeutic uses of lna-modified oligonucleotides |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| KR100909681B1 (ko) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| CA2474910A1 (en) * | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
| US7452987B2 (en) * | 2002-08-05 | 2008-11-18 | Silence Therapeutics Aktiengesellschaft (Ag) | Interfering RNA molecules |
| DK1606406T4 (da) * | 2003-03-21 | 2013-12-16 | Santaris Pharma As | Short Interfering RNA (siRNA) Analogues |
| US20040224405A1 (en) * | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| MX2007005558A (es) * | 2004-11-09 | 2008-01-31 | Santaris Pharma As | Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a. |
| DE102005030529A1 (de) * | 2005-06-30 | 2007-01-04 | Deutsche Telekom Ag | Verfahren und System zur Verteilung von Konfigurationen auf Clientrechner |
| WO2007085485A2 (en) * | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
-
2005
- 2005-01-28 EP EP05700612.4A patent/EP1713912B1/en not_active Expired - Lifetime
- 2005-01-28 US US10/587,775 patent/US20080249039A1/en not_active Abandoned
- 2005-01-28 WO PCT/DK2005/000062 patent/WO2005073378A1/en not_active Ceased
- 2005-01-28 DK DK05700612.4T patent/DK1713912T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005073378A1 (en) | 2005-08-11 |
| EP1713912A1 (en) | 2006-10-25 |
| US20080249039A1 (en) | 2008-10-09 |
| EP1713912B1 (en) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1713912T3 (da) | Modificerede Korte Interfererende RNA (Modificerede siRNA) | |
| EP1809748A4 (en) | Micrornas | |
| DE602005012035D1 (de) | Kontrast-Verstärkung | |
| NO20071430L (no) | Anti-OX4OL antistoffer | |
| EP1730701A4 (en) | MOBILE TICKETING | |
| ATE510923T1 (de) | Nukleinsäure | |
| EP1903334A4 (en) | BIOSENSOR | |
| DE502005008168D1 (de) | Pipette | |
| DE602005020768D1 (de) | Flammfestes kunstleder | |
| DE602005006185D1 (de) | Entwicklungsverfahren | |
| DE502005007322D1 (de) | Einpresskontakt | |
| DE602005027253D1 (de) | Herbizidresistenz verleihende gene | |
| EP1756129A4 (en) | NEW INTERCALATORS INTO THE DNA | |
| EP1909098A4 (en) | BIOSENSOR | |
| DE602006010164D1 (de) | Niedrigvolumenhybridisierung | |
| FI20040289A0 (fi) | Ohjattava pipetti | |
| DE602006009980D1 (de) | Biosensor | |
| EP1828115A4 (en) | 2-METHYLENE-19-NOR (20S) -1ALPHA-HYDROXYTRISHOMOPREGNACALCIFEROL | |
| DE502005000305D1 (de) | Photobioreaktor | |
| EP1831161A4 (en) | 2-METHYLENE-19-nor (20R) -1-ALPHA-HYDROXY-BISHOMOPREGNACALCIFEROL | |
| FIU20060462U0 (fi) | Pehmuste | |
| ATE378433T1 (de) | Haldenbioauslaugungsverfahren | |
| DE112004003049A5 (de) | Begasungseinrichtung | |
| DK1807520T3 (da) | RNA-konstruktioner | |
| AT500473B8 (de) | Inkubator |